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Abstract
Introduction Preliminary evidence supports the beneficial
role of physical activity on prostate cancer outcomes. This
phase III randomised controlled trial (RCT) is designed to
determine if supervised high-intensity aerobic and resistance
exercise increases overall survival (OS) in patients with
metastatic castrate-resistant prostate cancer (mCRPC).
Methods and analysis Participants (n=866) must have
histologically documented metastatic prostate cancer with
evidence of progressive disease on androgen deprivation
therapy (defined as mCRPC). Patients can be treatmentnaïve for mCRPC or on first-line androgen receptor-targeted
therapy for mCRPC (ie, abiraterone or enzalutamide) without
evidence of progression at enrolment, and with no prior
chemotherapy for mCRPC. Patients will receive psychosocial
support and will be randomly assigned (1:1) to either
supervised exercise (high-intensity aerobic and resistance
training) or self-directed exercise (provision of guidelines),
stratified by treatment status and site. Exercise prescriptions
will be tailored to each participant’s fitness and morbidities.
The primary endpoint is OS. Secondary endpoints include
time to disease progression, occurrence of a skeletal-related
event or progression of pain, and degree of pain, opiate
use, physical and emotional quality of life, and changes in
metabolic biomarkers. An assessment of whether immune
function, inflammation, dysregulation of insulin and energy
metabolism, and androgen biomarkers are associated
with OS will be performed, and whether they mediate the
primary association between exercise and OS will also be
investigated. This study will also establish a biobank for future
biomarker discovery or validation.
Ethics and dissemination Validation of exercise as
medicine and its mechanisms of action will create evidence
to change clinical practice. Accordingly, outcomes of this RCT
will be published in international, peer-reviewed journals, and
presented at national and international conferences. Ethics
approval was first obtained at Edith Cowan University (ID:
13236 NEWTON), with a further 10 investigator sites since
receiving ethics approval, prior to activation.
Trial registration number NCT02730338.

Strengths and limitations of this study
►► This is the first randomised controlled trial (RCT) to

examine exercise and overall survival in men with
prostate cancer.
►► This is a novel multinational, multicentre and multidisciplinary RCT with 24 months of supervised
tapered to self-managed exercise with behavioural
and psychosocial support, compared with self-directed exercise with psychosocial support alone,
in men with metastatic castrate-resistant prostate
cancer (mCRPC).
►► The study proposed will determine the efficacy of
an individually tailored, progressive and autoregulated aerobic and resistance exercise programme,
supervised by accredited exercise physiologists
(or equivalent) in addition to usual medical care, in
parallel with a health economics analysis to assess
the health benefits, additional costs and potential
savings of including exercise therapy as standard of
care for men with mCRPC.
►► The study has a translational team to investigate
biomarkers associated with three candidate pathways: systemic inflammation, insulin/glucose metabolism and androgen biosynthesis; to study how
they mediate the association between exercise and
overall survival; and to establish a blood, urine and
tissue biobank for future biomarker discovery or
validation.
►► The outcomes of this phase III RCT are limited to
men with mCRPC.

Introduction
An emerging body of literature supports the
role of exercise during cancer treatment as a
therapy which leads to improved outcomes,
both in quality of life and potentially
disease control.1 Identifying and evaluating
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on serum androgen levels remain elusive to date,13
with current studies limited by low patient numbers
and inadequate methods for measuring testosterone
levels in the low ranges seen in men on ADT.14 This is
especially true with the newer cyp17 inhibitors, such as
abiraterone. Additionally, high levels of inflammatory
biomarkers are associated with an increased risk of prostate cancer-specific mortality,15 and exercise is known
to lower levels of circulating inflammatory biomarkers
(eg, interleukin (IL)-6) in elderly populations.16 17
Increased physical activity may also produce epigenetic
modulations that may inhibit tumour cell proliferation,
such as altering histone deacetylase pathways. Exercise
and dietary changes may also lower cholesterol, which
epidemiological studies have suggested are associated
with decreased risk of prostate cancer and progression of
prostate cancer.18 19 Together, these observations suggest
that exercise interventions with patients with prostate
cancer may improve disease outcomes and quality of life.
However, given the highly suggestive observational findings, an RCT is warranted to establish clear causal relationships and guide clinical recommendations.
The primary objective of the GAP4 Intense Exercise for
Survival among Men with Metastatic Castrate-Resistant
Prostate Cancer (INTERVAL-GAP4) study is to determine if high-intensity aerobic and resistance training
plus psychosocial support increases OS compared with
self-directed exercise (non-supervised exercise recommendations) plus psychosocial support, in patients with
metastatic castrate-resistant prostate cancer (mCRPC).
OS was chosen as the primary endpoint because it has
clear biological, clinical and public health significance
and is a validated endpoint for approval of new treatments among men with mCRPC. Additionally, OS data
can be obtained with minimal loss to follow-up through
review of medical and death records.
The secondary objectives are to compare time to disease
progression, time to first occurrence of a symptomatic
skeletal-related event (SSE), time to progression of pain,
degree of pain, opiate use, physical and emotional quality
of life, and change in levels of biomarkers of inflammation,
energy metabolism and androgen metabolism between
the supervised exercise and self-directed exercise groups.
It will also be determined as to whether biomarkers of
immune function, inflammation, energy metabolism and
androgen metabolism are associated with OS among men
with mCRPC, and the extent to which these biomarkers
mediate the hypothesised association between high-intensity aerobic and resistance exercise and survival will be
explored.
We hypothesise that men with mCRPC randomised to
the supervised exercise arm will experience longer OS
and time to disease progression, less SSE and progression of pain, less pain and opiate use, better physical
function and quality of life, and more favourable levels
of inflammatory, energy metabolism and other metabolic
biomarkers compared with those in the self-directed exercise arm.
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low-toxicity adjuvant interventions, such as exercise,
that can be combined with standard therapy to improve
outcomes for men with prostate cancer is a high priority
and has the potential to have a large impact on the clinical and public health burden of prostate cancer.
In 2006, Galvão et al2 reported that resistance exercise
and programmes with resistance and aerobic exercise
improved physical function and the quality of life in men
without metastases on androgen deprivation therapy
(ADT) for prostate cancer. These results were expanded
in a subsequent report. Galvão et al3 showed that combined
resistance and aerobic exercise reversed the loss of
muscle mass and improved the quality of life in patients
with prostate cancer on ADT. In addition, Kenfield et al4
reported that vigorous aerobic exercise after prostate
cancer diagnosis was associated with a 60% lower risk of
fatal prostate cancer and a 49% lower risk of all-cause
mortality among men initially diagnosed with localised
disease. The dose-specific effect of larger quantities of
vigorous physical activity having greater survival benefit
has also been reported by Friedenreich et al.5 In addition,
one prospective study reported that resistance exercise
was associated with a 33% lower risk of all-cause mortality
in male and female cancer survivors while overall physical
activity was not.6 These findings emphasise the potential
benefits of exercise as an adjuvant treatment in prostate
cancer. However, data on exercise and cancer survival to
date have been from observational studies in which bias
from confounding and reverse causation are of concern.
Thus, a randomised controlled trial (RCT) is needed
to test whether exercise, in particular higher intensity
aerobic exercise and resistance exercise, impacts overall
survival (OS) in men with prostate cancer. Additionally,
treatment-related fatigue is a common side effect in men
with advanced prostate cancer, and exercise may decrease
fatigue and increase adherence to treatment regimens.7–9
While the prevailing view among patients and clinicians
has been that exercise may be problematic for patients
with cancer with advanced disease, recent research has
demonstrated tailored resistance and aerobic exercise to
be well tolerated, safe and effective for improving physical structure and function.10 Moreover, in patients with
bone metastases, a highly tailored exercise prescription
implementing a modular, multimodal approach and
avoiding excessive loading of the skeletal lesions has been
demonstrated to be safe and effective.10
There are many potential mechanisms by which exercise may lower risk of prostate cancer progression.1 11 12
Exercise influences all hormonal systems in the body,
including key hormones relevant to prostate cancer,
such as testosterone, growth hormone, insulin and insulin-like growth factor-1 (IGF-1). The androgen receptor
(AR) and its transactivation by ligand are among the
most important determinants of prostate cancer progression. Measurements of serum androgens (including its
receptors and binding proteins) provide an important
biomarker for the effectiveness of androgen deprivation
and prostate cancer progression. The effects of exercise

Open Access
(1:1) to either supervised exercise or self-directed exercise following the provision of written informed consent,
confirmation of clinical eligibility and successful completion of screening assessments (figure 1). This programme
design has been chosen as it would be unethical to ask
men with advanced prostate cancer to abstain from exercise for a 2-year period, owing to the documented health
benefits of exercise in patients with prostate cancer with
early-stage disease. Accordingly, men randomised to the

Figure 1 Schematic overview of the INTERVAL-GAP4 trial. 1RM, one-repetition maximum; ACSM, American College of Sports
Medicine; CPET, cardiopulmonary exercise test; ECG, echocardiogram; INTERVAL-GAP4, Intense Exercise for Survival among
Men with Metastatic Castrate-Resistant Prostate Cancer, Global Action Plan 4.
Newton RU, et al. BMJ Open 2018;8:e022899. doi:10.1136/bmjopen-2018-022899
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Methods
Study design
This is a multinational and multicentred, randomised
controlled phase III clinical trial (INTERVAL-GAP4)
recruiting 866 men with mCRPC to determine if supervised high-intensity aerobic and resistance training with
psychosocial support increases OS compared with printed
exercise recommendations (self-directed exercise) with
psychosocial support. Patients will be randomly assigned

Open Access

Participants
Men with histologically documented adenocarcinoma of
the prostate and progressive systemic metastatic disease
despite castrate levels of testosterone (<50 ng/dL) due to
orchiectomy or luteinising hormone releasing hormone
(LHRH) agonist (defined as mCRPC), and who meet
study inclusion (box 1) and exclusion (box 2) criteria
will be recruited to the study. This patient population was
chosen because the median OS among men with mCRPC
is 329 to 358 months; thus, OS is a feasible outcome to
examine within the budget and timeline of the proposed
study when using patients with mCRPC as the target
population. At enrolment, patients can be either treatment-naïve for mCRPC or on first-line AR-targeted
therapy for mCRPC (ie, abiraterone or enzalutamide)
without evidence of progression. Patients will be required
to remain on ADT with a GnRH agonist/antagonist for
the duration of their involvement in the study or have
had prior bilateral orchiectomy. At enrolment, patients
may have received chemotherapy for hormone-sensitive stages of the disease. Patients cannot have received
chemotherapy for castrate-resistance status at enrolment.
Patients are not permitted to be on any experimental
therapies at enrolment; however, patients may be treated
with chemotherapy or any other therapies for mCRPC
postenrolment and randomisation.

Box 1

Inclusion criteria

►► Histologically documented adenocarcinoma of the prostate with

progressive systemic metastatic disease, despite castrate levels of
testosterone (<50 ng/dL). Castrate levels of testosterone must be
maintained while on study.
►► At enrolment, patients may be clinically eligible through two
pathways:
–– Pathway A: currently on abiraterone and/or enzalutamide and not
progressing.
–– Pathway B: preabiraterone and pre-enzalutamide with progressive disease.
►► Progressive disease must be demonstrated by one or more of the
following criteria:
1. Measurable disease progression:
–– >20% increase in the sum of diameters of measurable lesions
from the time of maximal regression; or the appearance of
one or more new nodal, visceral or skeletal lesions.
2. Bone scan progression:
–– Appearance of one or more new lesions on a bone scan that is
attributable to prostate cancer.
3. Prostate-specific antigen (PSA) progression:
–– PSA≥2 ng/mL that has risen serially on at least two occasions,
each at least 1 week apart (PSA1<PSA2<PSA3).
►► Patients must be on androgen deprivation therapy (ADT) with a
gonadotropin-releasing hormine (GnRH) agonist/antagonist or prior
bilateral orchiectomy. All patients are required to be on ADT during
the study period.
20
►► Receive a Halabi nomogram score <195, classified as low or intermediate risk.
►► Eastern Cooperative Oncology Group performance status score ≤1.
►► Age ≥18 years.
►► Be willing to travel to one of the exercise facilities for exercise testing and training.
►► Be willing to use the technological aspects of the trial for patient
monitoring and support.
►► Fluent in the language designated by the institution where the patient will be enrolled.
►► No major surgery ≤4 weeks at enrolment and fully recovered from
any prior surgery.
►► Medical clearance to complete a symptom-limited cardiopulmonary
exercise test (CPET) with electrocardiography, and to complete a
structured and progressive resistance and aerobic exercise programme of moderate-to-vigorous intensity.
►► Must pass the CPET performed at screening (pre-enrolment), judged
as achieving a rating of perceived exertion ≥9 on the 10-point Borg
Scale with no detected cardiac abnormalities. Patients with any abnormalities noted are permitted to enrol following cardiologist review and clearance.
►► Meet the required baseline laboratory values: absolute neutrophil count
(ANC)≥1.5×109/L (≥1500/μL); platelet count≥100x109/L (≥100 000/
μL); creatinine≤1.5× upper limits of normal; bilirubin≤1.5× upper limits of normal; aspartate aminotransferase (AST)≤1.5× upper limits of
normal; and serum testosterone≤50 ng/dL.
►► Patients with bone metastases must be cleared by the Exercise
Coordination Centre following review of their most recent bone scan
to ensure they are able to participate in most exercises required by
the trial.

Screening
Once referred to the trial through patients’ managing
clinician, and consented to the trial by an independent
research officer, patients will undergo a screening process
to confirm eligibility, with baseline measures taken prior
to randomisation and completion of baseline exercise
testing, if eligible. Measures necessary to complete the
multivariable nomogram (http://www.cancer.duke.edu/
Nomogram/firstlinechemotherapy.html)20 risk assessment are mandatory, including the presence of nodal,
bone and/or visceral metastases; the use of opioid analgesics; Eastern Cooperative Oncology Group performance
status (must be ≤1); and the collection of standard-ofcare pathology (lactate dehydrogenase (LDH), albumin,
haemoglobin, alkaline phosphatase (ALP), prostate-specific antigen) within 28 days prior to baseline assessments.
Patients must have a Halabi nomogram risk of low or
intermediate (<195)20 to confirm clinical eligibility prior
to attempting a symptom-limited, medically supervised
cardiopulmonary exercise test (CPET) with echocardiogram (ECG) recording.
Patients who are currently participating in vigorous
aerobic activity (>60 min per week) and/or structured

resistance training (≥2 days per week) will be excluded.
Patients must have no known contraindications to high-intensity aerobic or resistance exercise as determined by
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control arm are free to engage in exercise under their
own management (self-directed exercise), where changes
in physical activity of both groups will be monitored.
The trial was prospectively registered on 10 March 2016
(https://clinicaltrials.gov/ct2/show/NCT02730338),
prior to patient recruitment commencing, with the trial
now recruiting.

Open Access
Exclusion criteria

►► No previous progression while on treatment with abiraterone and/

or enzalutamide.
►► No prior chemotherapy for metastatic castrate-resistant prostate

cancer.
►► Not currently receiving experimental treatment with non-approved

drugs at enrolment.
►► No known brain metastases.
►► No known spinal cord compression, compromise or instrumentation

due to metastatic disease. Radiation therapy for metastatic disease
is allowed.
►► No moderate to severe bone pain (Common Terminology Criteria
for Adverse Events (CTCAE) V.5.0 grading criteria).
►► No history of hypertension that is not well controlled.
►► No congestive heart failure.
►► No recent serious cardiovascular events (within 12 months), including but not limited to, transient ischaemic attack, cerebrovascular
accident or myocardial infarction.
►► No medical condition, such as uncontrolled infection or cardiac disease, which in the opinion of the relevant physician would make this
protocol unreasonably hazardous for the patient.
►► No serious or non-healing wound, ulcer or bone fracture.
►► Not experiencing shortness of breath, chest discomfort or palpitations when performing activities of daily living.
►► Does not have chest pain generated by physical activity and has not
developed chest pain in the previous month.
►► No peripheral neuropathy grade ≥3 (CTCAE V.5.0 grading criteria).
►► No psychiatric illness.
►► No small cell neuroendocrine tumours or pure small cell carcinoma
of the prostate.
►► No current active second malignancy other than non-melanoma
skin cancer.
►► Not participating in vigorous aerobic exercise for more than 60 min
per week.
►► Not participating in structured resistance exercise for ≥2 sessions
per week.

treatment status (ie, abiraterone or enzalutamide, yes/no;
and radium-223, yes/no) as these therapies have a proven
effect on progression-free survival.8 9 A research officer at
the SCC with no patient contact will be responsible for
uploading the randomisation schedule into the Research
Electronic Data Capture (REDCap; a secure application
for building and managing online surveys and databases). Site-based research coordinators will subsequently
randomise patients through the REDCap system once
approval from the SCC is received. Patients will not be
informed of their group allocation until after the completion of their baseline visit to maintain the integrity of effort
and the results of assessments performed. At the baseline
visit, participants will complete all remaining assessments
including physical function tests (ie, strength tests and
400 m walk test), fasting blood and first-void urine collection (ie, for correlative studies and biorepository storage),
and any remaining questionnaires. Patients randomised to
the supervised exercise arm will be enrolled into an automated text messaging programme to provide behavioural
support, and participants in both arms will commence an
automated newsletter education programme, circulated at
the beginning of each cycle, intended to provide psychosocial support and enhance quality of life.
Outcomes
Measurements
This trial comprised a 96-week on-treatment period,
approximating 2 years (24 cycles with each cycle spanning
28 days), followed by a 3-year follow-up period. Assessments are conducted at baseline and at routine intervals
throughout the on-treatment period (table 1). After the
on-treatment phase ends, patients will enter the follow-up
phase of the trial, where their medical records and
death certificates will be reviewed quarterly to quantify
the primary endpoint of OS and prespecified secondary
endpoints.

their physicians. Following medical clearance, patients
will be required to complete a series of baseline questionnaires and will attempt the symptom-limited CPET
with ECG using a stationary, electronically braked cycle
ergometer. Patients who successfully pass their CPET
(ie, no cardiac abnormalities while achieving a maximal
rating of perceived exertion (RPE ≥9 of the 10-point Borg
Scale)) will have their study information reviewed by
the Exercise Coordination Centre (ECC; Edith Cowan
University, Perth, Australia) for suitability of exercise
prescription within the INTERVAL-GAP4 programme,
with consideration given to the location, number and
severity of bone metastases; and the Study Coordination Centre (SCC; University of California San Francisco (UCSF), California, USA) to confirm all clinical and
study eligibility requirements prior to randomisation and
subsequent baseline testing.

Primary endpoint
Overall survival
OS is the primary outcome of this RCT. It is a validated
endpoint for the approval of new treatments in medicine, and feasible within the budget and timeline of
the study as men with mCRPC have a median survival
of 32–35 months.8 9 Patients will be followed for death a
minimum of 36 months after randomisation. OS will be
measured from the time of randomisation until death.
Medical records and death certificates will be reviewed
every 3 months to obtain survival status. Country-specific
mortality databases will also be searched annually; cause
of death will be determined through review of medical
and death records. Importantly, quantification of OS
through review of medical records and death certificates
reduces loss to follow-up and missing data.

Randomisation
Patients will be centrally randomised by the SCC in a ratio
of 1:1 to the two study arms, using block randomisation
in random blocks of 2, 4 and 6, and stratified by site and

Secondary endpoints
Disease progression
Disease progression will be examined through review of
patient medical records every six cycles and measured
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X

 Randomisation

X

 Medication/treatment history

X

X

 Vital signs

 ECOG performance status

X

 Concomitant medications

X

X

4

X

5

X

X

X

X

X

X

X

X

X

X

X

6

X

7

X

8

X

X

X

X

9

X
Request
X

 FFPE tumour specimens

 Urine specimens

X

X
X

X
X

X
X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

10

X

X

X

11

Transition

Assessed at each supervised exercise visit using VAS

 Research blood (fasting)

Metabolic research studies

X

 Adverse events‡

 Bone pain at exercise visits

X

 Medical clearance
X

X

 Exercise testing—self-directed
arm

Safety

X

X

X

3

X

X

2

 Exercise testing—supervised arm X

X

1

X

X

0

X

 WHO Analgesic Scale

 Overall survival, disease
progression, symptomaticskeletal event†

Efficacy

 Fasting lipid profile, fasting
glucose, haemoglobin A1c

 CBC w/diff, blood chemistries

Lab studies

 Weight, waist, hip circumference, X
height (at baseline only)

Body measurements

X

 Medical history*

Clinical history

X

 Informed consent

Cycle 0:
Screening baseline Supervised exercise

On-treatment study period (each cycle=28 days)

Summary of INTERVAL-GAP4 assessments

X

X

X

X

X

X

X

X

X

X

X

X

X

X

12

X

X

X

13

X

X

X

14

X

X

X

X

X

X

15

X

X

X

16

X

X

X

17

X

X

X

X

X

X

X

X

X

X

X

18

X

X

X

19

Self-managed exercise programme

X

X

X

20

X

X

X

X

X

X

21

X

X

X

22

X

X

X

23

X

X

X

X

X

X

X

X

X

X

X

X

X

X

24

Continued

Once
yearly

Twice
yearly

Follow-up
period

Offtreatment
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 Cycle

Table 1
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Continued

X

X

X

X

X

Self-managed exercise programme

X

X

X

X§

Follow-up
period

*New conditions diagnosed on-study are recorded during the on-study period.
†Per review of medical records or other documentation. Mortality data will be collected through medical records, death records and other resources every 6 months during the on-treatment
and follow-up periods. If the participant is lost to follow-up, we will contact next of kin or alternate contact. Death certificates will also be requested and all medical information pertaining to
the death will be centrally reviewed to determine cause of death.
‡Continuously reported from informed consent until 28 days after cycle 24, day 1.
§Selected assessments will be administered during the follow-up period on a yearly basis. If no response is received from the participant and medical records do not indicate death, we will
follow up with next of kin or alternate contact.
CBC, Complete Blood Count; WHO, World Health Organisation; VAS, Visual Analog Scale; ECOG, Eastern Cooperative Oncology Group; FFPE, formalin-fixed paraffin-embedded; INTERVALGAP4, Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer - Global Action Plan 4

X

X

Transition

Offtreatment
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 Food Frequency Questionnaire

 Exercise, quality of life and
X
memory questionnaires (3-month
or 6-month intervals, depending
on survey)

 Exercise screening questionnaire X
X

On-treatment study period (each cycle=28 days)

Cycle 0:
Screening baseline Supervised exercise

 Demographics and health history X
questionnaire

Patient-reported outcomes

Table 1
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Source

Criterion

Bone scan

Appearance of ≥2 new lesions on
bone scan, for bone scans that are
completed >12 weeks following
randomisation.
≥20% increase in the sum of lesion
diameters, taking the reference as the
smallest sum on study. In addition to this
relative increase by 20%, the sum must
also demonstrate the following:
►►an absolute increase>5 mm, OR
►►the appearance of one or more new
lesions, OR
►►unequivocal progression of baseline
non-measurable lesions.

CT/MRI scans

mCRPC therapy
initiation

Symptomatic
skeletal events

Development of an indication for
initiating a therapy for mCRPC after
randomisation, including but not
limited to, abiraterone, enzalutamide,
chemotherapy or radiation therapy.
Development of a symptomatic skeletalrelated event that must be attributable to
disease.

Progression will be defined based on Prostate Cancer Working
Group 3 (PCWG-3) and Response Evaluation Criteria in Solid
Tumours (RECIST) 1.1 as all other lesions, including small
lesions (longest diameter <10 mm or pathological lymph nodes
10 to <15 mm short axis) as well as truly non-measurable lesions.
All non-measurable lesions will be recorded at baseline. If patients
have measurable disease, there must be overall worsening in
non-measurable disease such that the overall tumour burden has
increased substantially. The designation of disease progression
solely on the basis of change in non-measurable disease in the
face of stable disease or partial response of the measurable
disease is extremely rare.
mCRPC, metastatic castrate-resistant prostate cancer; CT,
computed tomography; MRI, magnetic resonance imaging.

by the treating physician based on the Prostate Cancer
Trials Working Group 3 (PCWG-3)21 and Response Evaluation Criteria in Solid Tumours (RECIST) 1.122 criteria
to determine and monitor specific indications of disease
progression (table 2). Time to disease progression will
be measured from randomisation until the first of the
following: first CT or bone scan documenting disease
progression, initiation of a new therapy for mCRPC (clinical progression) or first occurrence of an SSE.
Symptomatic skeletal-related events
Time to the first occurrence of an SSE will be defined as
the time from randomisation to documentation of any of
the following: (1) use of external beam radiation therapy
to relieve bone pain, (2) occurrence of new symptomatic pathological bone fractures excluding asymptomatic
compression fractures, (3) known spinal cord compression, (4) change in antineoplastic therapy to treat bone
pain or (5) surgical intervention to treat bone pain. This
8

information will be determined through adverse event
(AE) recordings, concomitant medication and treatment
reviews, and patient medical record reviews.
Progression of pain, degree of pain and opiate use
Analgesic or opiate use will be assessed using the Brief
Pain Inventory-Short Form (BPI-SF), the WHO Analgesic
Scale and medical record review at entry with a lead-in
period of <28 days. The WHO Analgesic Scale will be
completed every three cycles (and confirmed by medical
review), with the BPI-SF administered every three cycles
until cycle 24 and annually thereafter.
Immune status, inflammation, energy metabolism and androgen
metabolism
Fasted serum, plasma and buffy coat samples (26 mL per
visit) and first-void urine will be collected (with 4 mL of
urine aliquots stored) at cycles 0, 6, 12 and 24. Serum
and plasma aliquots will be used to interrogate a panel
of markers associated with immune function and inflammation, such as interleukin (IL1β, IL-2, IL-6), tumour
necrosis factor-α, adiponectin and C reactive protein.
Energy metabolism will be investigated through markers
including serum insulin, plasma glucose, C-peptide and
IGF-1. Androgen metabolism will be explored through
biomarkers including testosterone, dihydrotestosterone,
androstenedione, dehydroepiandrosterone, 17-hydroxyprogesterone, 17-hydroxypregnenolone, sex hormone
binding globulin and progesterone using mass spectrometry. The study is funded to analyse immune, inflammation, energy metabolism markers at the four collection
time points, and androgen metabolism markers at cycles
0 and 6. Samples will be stored in regional biorepositories
across the globe throughout the trial in −80°C biomedical freezers prior to batch analyses at the completion of
the trial, for all patients who provided consent for this to
occur at randomisation.
Physical function
Muscle strength will be assessed using a one-repetition
maximum (1RM) test for chest press, leg press, seated
row and/or leg extension, depending on the location and severity of any bone metastases (table 3),9 11 23
recorded in kilograms. Functional performance will be
assessed through the 400 m walk test, recording time
to completion (in seconds) with heart rate maximum
(HRmax), heart rate average (HRavg) and heart rate
recovery (HRR) quantified. Aerobic fitness will be
assessed through a medically supervised CPET to determine patient VO2 peak (LO2/min and mlO2kg/min) and
maximum workload (Watts) during a successful CPET
(RPE ≥9, using the 10-point Borg Scale).24 Physical function assessments are performed every three to six cycles
across the 2-year on-trial period as previously described
(table 1).2 10
Quality of life
Quality of life is measured through questionnaires every
three cycles, including the Functional Assessment of
Newton RU, et al. BMJ Open 2018;8:e022899. doi:10.1136/bmjopen-2018-022899
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Table 2 Criteria for the establishment of disease
progression following randomisation
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Period

Resistance exercise

Aerobic exercise

Cycle 0 (week 1)
 Session 1

1 set × 8RM × 6 exercises

3×30 s at RPE (5), with 90 s recovery
10 min at RPE (4) (with 2 min recovery as needed)

 Session 2
 Session 3

1 set × 12RM × 6 exercises

3 × 30 s at RPE (5), with 90 s recovery

2 sets × 8RM × 6 exercises

4 × 30 s at RPE (6), with 90 s recovery

Cycle 0 (week 2)
 Session 1

10 min at RPE (4) (with 2 min recovery as needed)

 Session 2
 Session 3

2 sets × 120RM × 6 exercises

4 × 30 s at RPE (6), with 90 s recovery

3 sets × 8RM × 6 exercises

3 × 60 s at RPE (6), with 120 s recovery

Cycle 0 (week 3)
 Session 1

15 min at RPE (5) (with 2 min recovery as needed)

 Session 2
 Session 3

3 sets × 12RM × 6 exercises

3 × 60 s at RPE (6), with 120 s recovery

Cycle 0 (week 4–de-load)
 Session 1

2 sets × 8RM × 6 exercises

 Session 3

3 × 30 s at RPE (6), with 90 s recovery
10 min at RPE (4) (with 2 min recovery as needed)

 Session 2
2 sets × 12RM × 6 exercises

3 × 30 s at RPE (6), with 90 s recovery

Additional descriptions
 INTERVAL-GAP4 prescription provides a gradually incremental introduction to the exercise programme across cycle 0
(weeks 1–4). This familiarises and prepares patients for their subsequent participation in moderate-to-high load resistance
exercise, as well as high-intensity interval and moderate-intensity continuous aerobic exercise. This cycle also contains
a de-load week to increase recovery and promote adaptation prior to progressing into the full prescription. Programme
intensity is provided through a repetition maximum (RM) and rating of perceived exertion (RPE) system to support exercise
autoregulation and patient management throughout cancer treatment and disease progression as needed.11

Cancer Therapy-G; Functional Assessment of Chronic
Illness Fatigue subscale; European Organisation of
Research and Treatment of Cancer Quality of Life Questionnaire 30; Expanded Prostate Cancer Index Composition 26; EuroQOL 5 Dimensions Questionnaire (EQ5D);
State-Trait Anxiety Inventory, Center for Epidemiologic
Studies Depression; and Pittsburgh Sleep Quality Index
questionnaire.
Programme safety
All AEs will be graded according to the National Cancer
Institute’s Common Terminology Criteria for Adverse
Events (V.4.0), and will be assessed at every exercise
testing and training visit. AEs will also be collected in both
groups once per month by telephone. AE type, severity,
attribution (disease-related or exercise-related), expectedness and timing will be recorded on case report forms.
Serious adverse events (SAEs) include events that may
be life-threatening, require and/or prolong inpatient
hospitalisation, result in persistent or significant disability
or incapacity, or result in death. AEs expected on-trial
include bone pain, pathological skeletal fracture, musculoskeletal injury, joint pain, falls and/or muscle soreness.
All patients regardless of group will require medical clearance following AEs prior to recommencing their exercise
programme.

Health economics
An economic evaluation will be performed in parallel to
the trial to assess the health benefits, additional costs and
potential savings of including exercise therapy as standard of care for men with mCRPC. This health economics
protocol will inform the relative value for money of exercise medicine compared with other healthcare interventions in this patient population and stage of disease.
Hospital resource consumption and associated costs will
also be obtained to assess costs for secondary healthcare
utilisation between the intervention and control groups
(supervised exercise and self-directed exercise, respectively). All hospital events, including emergency department attendances and admissions, outpatient visits and
procedures, and inpatient admissions for all causes will
be explored to quantify and identify potential disease-related (prostate cancer) events, as well as total healthcare
resource use for all other purposes inclusive of comorbidities and other chronic diseases. The cost of providing
the supervised exercise and self-managed intervention
will also be quantified. Due to the international distribution of investigator sites involved in this study, a regional
(country by country) and global (pooled) analysis will be
conducted to account for regional differences in healthcare systems, coverage and costs.

Newton RU, et al. BMJ Open 2018;8:e022899. doi:10.1136/bmjopen-2018-022899
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Table 3 Exercise prescription for cycle 0 (weeks 1–4), a fully supervised introduction to exercise while incrementally building
exercise capacity
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Patient programmes
Exercise prescription
Patients assigned to the intervention arm will receive a
96-week, individualised (ie, based on a needs analysis and
physical assessment of patient condition and capacity),
periodised (ie, the systemic organisation of exercise

variation into microcycles (weekly), mesocycles (monthly)
and macrocycles (annually)), progressive and autoregulated (ie, patients progress at their own pace based on variations in health, performance capability, fatigue, recovery
capacity or scheduling commitments, with adjustments
made each session according to patients’ capacity on the
day of exercise training) programme, consisting of structured resistance exercise and combinations of high-intensity interval training and moderate-intensity continuous
training aerobic exercise (table 3 and 4). The initial 48
weeks of the programme (year 1) will be supervised in an
exercise clinic setting, with a gradual tapered transition
to self-management, and the subsequent 48 weeks of the
programme (year 2) will be self-managed with one exercise visit required at the beginning of each cycle (every
4 weeks). This exercise prescription critically uses periodisation to maximise training stimulus and physiological
adaptation while also reducing the risk of injury, overtraining or staleness,11 26 autoregulation to allow patients
with advanced mCRPC to self-determine their capabilities at each session collaboratively with the supervising
clinical exercise physiologist, thereby lowering intensity
or volume if the patient is fatigued or unwell, or raising
intensity or volume if the patient is energetic and motivated.11 26 Furthermore, the exercise programme will
be modified for any patients with mCRPC with bone

Table 4 Exercise prescription for cycles 1–11 (weeks 5–48): a progressive, periodised and autoregulated programme with deload weeks, tapering supervision to self-management
Period

Resistance exercise

Cycles 1–11 (week 1)
 Session 1

4 sets × 8RM × 6 exercises

6 × 60 s at RPE (8), with 120 s recovery
30–40 min at RPE (5) (with 2 min recovery as needed)

 Session 2
 Session 3

Aerobic exercise

4 sets × 12RM × 6 exercises

6 × 60 s at RPE (8), with 120 s recovery

4 sets × 6RM × 6 exercises

6 × 30 s at RPE (9), with 90 s recovery

Cycles 1–11 (week 2)
 Session 1

30–40 min at RPE (6) (with 2 min recovery as needed)

 Session 2
 Session 3

4 sets × 10RM × 6 exercises

6 × 30 s at RPE (9), with 90 s recovery

3 sets × 8RM × 6 exercises

6 × 60 s at RPE (8), with 120 s recovery

Cycles 1–11 (week 3)
 Session 1

30–40 min at RPE (5) (with 2 min recovery as needed)

 Session 2
 Session 3

3 sets × 12RM × 6 exercises

6 × 60 s at RPE (8), with 120 s recovery

Cycles 1–11 (week 4–de-load)
 Session 1

2 sets × 6RM × 6 exercises

 Session 3

4 × 30 s at RPE (6), with 90 s recovery
30–40 min at RPE (4) (with 2 min recovery as needed)

 Session 2
2 sets × 10RM × 6 exercises

4 × 30 s at RPE (6), with 90 s recovery

Additional descriptions
 INTERVAL-MCRPC prescription provides a periodised, progressive and individually tailored programme consisting of
moderate-to-high load resistance exercise, combined with high-intensity interval and moderate-intensity continuous aerobic
exercise. Each cycle contains a de-load week to increase recovery and promote adaptation. Programme intensity is provided
through a repetition maximum (RM) and rating of perceived exertion (RPE) system to support exercise autoregulation
throughout cancer treatment and disease progression as needed.11

10
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Data on health benefits and costs will be appropriately
adjusted for covariates, such as age, common comorbidities (eg, diabetes, cardiovascular disease) and body mass
index. Health benefits will be measured using quality of
life derived from the EQ5D and converted to a health
utility scale using regional norms (where possible) to
derive quality-adjusted life years for cost utility analysis. Given the duration of this multinational RCT, costs
associated with health resource use and delivery of the
supervised exercise intervention will be standardised to
a common year. Incremental costs and benefits will be
subsequently estimated and reported as an incremental
cost effectiveness ratio, which will be bootstrapped25 to
identify 95% CIs. This will be subsequently used to quantify the probability of whether the intervention is good
value for money, and the level of risk for patients with
mCRPC not being ‘better-off’ by receiving supervised
exercise (ie, the intervention). Deterministic sensitivity
analysis will be undertaken to identify the main drivers of
the costs, outcomes and value for money.

Open Access

Aerobic
Flexibility
Metastases Resistance
site
Upper Trunk Lower WB NWB Static
Pelvis
Lumbar
spine

√*
√*

Thoracic
spine/ribs

√*

Proximal
femur
All regions

√*
√*

√

√†
√†

√
√

√‡
√‡

√

√‡

√†

√

√‡

√†

√

√‡

√†
√

√

*Exclusion of shoulder flexion/extension/abduction/adduction—
inclusion of elbow flexion/extension.
†Exclusion of hip extension/flexion—inclusion of knee extension/
flexion.
‡Exclusion of spine/flexion/extension/rotation.
√, target exercise region; mCRPC, metastatic castrate-resistant
prostate cancer; NWB, non-weight bearing (eg, cycling); WB,
weight bearing (eg, walking).

Behavioural support
Patients assigned to the supervised exercise arm will
also receive behavioural support to help promote
programme adherence and compliance when tapering
to self-management. Behavioural support is provided in
text message format, the overarching focus of which will
be to increase perceived control in task-specific exercises
and assist patients with overcoming individual barriers
to exercise, rooted in the social cognitive theory and
the theory of planned behaviour constructs.28–30 The level
of behavioural support provided will increase as patient
self-management increases, providing one text per week
(cycle 0), two texts per week (cycles 1–8), three texts per
week (cycles 9–11) and five texts per week (cycles ≥12).
Some text messages will ask patients to provide a response
in a return text message to heighten patient engagement.
Psychosocial support
Psychosocial support will be provided to all patients in
the trial. Participants will be given a digital or mailed
newsletter of two to three pages each month, to provide
education and information on topics relevant for men
with advanced prostate cancer, including, but not limited
to, staying healthy, lifestyle behaviours, goal setting,
managing fatigue, bone health, side effects of treatment,
managing side effects, depression, social support, pain
management, sexual intimacy, cognitive changes and
gaining control.

metastases depending on the size and location of metastases (table 5), performed individually or in small groups
(of up to 4–6 patients per session).
Resistance exercise intensity is prescribed using the
repetition maximum (RM) method, which is monitored
and adjusted throughout the programme, with weight
increased or decreased as the patient becomes stronger
or weaker (ie, 8RM refers to the highest amount of weight
a patient can lift eight times per set). Resistance training
repetitions will not be performed to the point of neuromuscular failure, but rather the set will be ceased 1–2
repetitions short of the patient being unable to complete
a repetition. Performing resistance training sets to neuromuscular failure are unlikely to provide additional benefit
in non-athlete populations.27
Aerobic exercise intensity is prescribed using the RPE
method, where aerobic ergometer resistance or speed
will be adjusted to elicit the target RPE throughout the
trial. A confirmatory, supervised aerobic assessment—
the constant load test (CLT)24—will be conducted at the
start of each cycle to monitor aerobic fitness progression
across the exercise programme including the self-management period. The CLT is a short, 3 min submaximal exercise test performed on a cycle ergometer at a
preset workload (70% of achieved CPET workload at
the screening visit), with a graded 4 min warm-up and
active 3 min unloaded cool-down (ie, 10 min total). This
CLT workload established at baseline remains constant
(unchanged) throughout the trial and is used to assess
programme effectiveness with HRmax, HRavg, HRR and
RPE recorded. Impact exercise is excluded from the exercise prescription for all patients as it is a contraindication
for patients with bone metastases, comprising over 80%
of patients with mCRPC.

Self-directed exercise group (control)
Patients randomised to the self-directed exercise group
will receive the psychosocial support described above.
In addition, these patients will also be provided with the
current American College of Sports Medicine guidelines
for physical activity for cancer survivors31 32 and print
information on how to pursue a self-directed exercise
programme.
This self-directed exercise strategy is being employed
as it would be unethical to ask men with advanced prostate cancer to abstain from exercise for a 2-year period,
owing to the documented health benefits of exercise in
patients with prostate cancer with early-stage disease.
Similarly, this trial uses a single-blinded study design
where it is not possible to blind patients to the intervention, and given recruited patients are at the end stage of
life the ability to provide supervised exercise to control
patients after trial completion to optimise patient retention is not an option. Thus, it is felt the provision of
printed material for self-directed exercise will assist with
patient retention for men randomised to the control
arm, who are free to exercise as much or as little as they
like.
There is considerable contrast in the effectiveness of
a supervised programme pursued in an exercise clinic
versus home-based and self-directed formats; thus, we
believe this design will differentiate the benefits of the
exercise intervention for the primary and secondary
outcomes and maintain interventional fidelity in the trial.
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Table 5 Modular, multimodal exercise programming for
patients with mCRPC with known bone metastases across
resistance, aerobic and flexibility training based on lesion
sites9 11 22
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Statistical considerations
Analysis will be performed using an intention-to-treat
approach,36 powered to detect an HR of 0.78 for OS
between patients randomised to the two treatment arms.
Given a total enrolment period of 36 months, an on-trial
period of 24×4 week cycles, a minimum of 36 months of
follow-up after the on-treatment period; survival time
following an exponential distribution; and a median OS
of 33.5 months in the self-directed exercise arm, the estimated sample size required to detect an HR of 0.78 with
80% power at significance level of 0.05 is 824 (ie, 412 men
in each arm). Accounting for up to 5% of patients with
missing data on OS, we aim to enrol 866 men (ie, 433 men
in each arm). Four interim analyses will be performed:
feasibility (completed in 2016), intervention effectiveness (first 15% of patients following the six cycles using
leg extension strength and 400 m walk test data), efficacy
(first 50% of patients following death to investigate OS)
and accrual assessment (quarterly analysis).

supervision of patients with advanced prostate cancer;
oversees exercise testing and training, and delivery of
the INTERVAL-GAP4 prescription; and manages exercise
data collection, auditing and implementation of the exercise management software (Physitrack, Brighton, UK).
All data entered into REDCap and Physitrack are de-identified (ie, using patients’ study identifier), with all forms
uploaded to REDCap de-identified (ie, all identifiable
information is redacted).
Patient and public involvement
Movember Foundation is a charitable organisation advocating for improved outcomes for men with prostate
cancer. As the funder of this global trial, with extensive
consumer representative networks (ie, patients, their
families and their carers) across the globe, the organisation is uniquely positioned to represent the views and
experiences of consumers in Australia, Canada, UK and
the USA (among others) who have engaged with Movember’s activities over the past 15 years. This unique viewpoint and experience have been used to ensure that
the study protocol engages participants in a respectful,
ethical and impactful way, while addressing the needs of
patients with mCRPC. Movember Foundation, with their
consumer representative networks, will also facilitate the
delivery of this study, by providing assistance with patient
recruitment and support, as well as the translation and
dissemination of the research findings to community
members, patients and cancer support groups. In addition, the research team of this study protocol includes
urologists and medical oncologists who work with the
target population on a daily basis, from which these clinicians have used patient priorities, patient experience and
patient preferences to help inform the development of
the research questions and outcome measures. Lastly, the
broader research team has conducted research studies in
exercise and prostate cancer involving large quantities of
participants over the course of the past 20 years, providing
feedback to investigators to help design better exercise
oncology clinical trials. This sizeable patient interaction
across the clinical and community landscape has contributed substantially to the design of this project.

Trial management
INTERVAL-GAP4 has several levels of management to
ensure the trial is appropriately governed and operational. The study protocol was established through a
Protocol Development Working Group with guidance
from a Steering Committee and Research Advisory
Committee, each independent from each other, with globally recognised leaders in clinical and academic contexts
pertaining to prostate cancer. Operationally, the INTERVAL-GAP4 trial is overseen by the Steering Committee
and comanaged by the ECC (Exercise Medicine Research
Institute, Edith Cowan University, Australia), the SCC
(Department of Urology, UCSF, USA) and the Global
Project Manager (Global Action Plan, Movember Foundation, Australia), with guidance from the Research
Advisory Committee. The trial also has a Protocol Amendment Review Committee to continually evaluate protocol
performance and review or approve proposed site-specific, investigator-led substudies.
INTERVAL-GAP4 has a Data Safety and Monitoring
Board (DSMB) to oversee the data monitoring of the trial,
and to monitor the safety of patients enrolled in the trial,
which is completely independent of all other governing
committees and site investigators. The trial also has a
Medical Monitor Team consisting of several urologists and
medical oncologists in Canada, UK and USA. The SCC
oversees site training, enrolment of patients (including
randomisation), study databases, clinical data collection
and data auditing, behavioural and psychosocial support
programmes, country-specific translations, AE and SAE
reporting, liaison with the Medical Monitors and DSMB,
and implementation of central data collection software
(REDCap, Vanderbilt University, Nashville, USA). The
ECC oversees site training of exercise physiologists and
professionals pertaining to exercise programming and

Ethics and dissemination
Ethics approval was first obtained at Edith Cowan University (ID: 13236 NEWTON), with a further 10 investigator
sites in Australia, Canada, Europe, UK and USA since
receiving site-specific human research ethics approval,
prior to site activation and recruitment commencement.
All future investigator sites joining the INTERVAL-GAP4
study are required to obtain site-specific human research
ethics committee approvals, undergo site-based education and training, and receive a site initiation visit prior
to opening for recruitment. Future amendments to
the protocol and associated documentation, if any, will
be deliberated and approved by the Protocol Amendment Review Committee, followed by submission to and
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To date, research into unsupervised exercise programmes
in cancer populations has shown limited effectiveness.33–35
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Discussion
Preliminary evidence supports the potential beneficial
role of exercise for prostate cancer survival. Exercise
has potential as a low-toxicity adjuvant medicine that
can be combined with standard cancer therapies to
improve patient outcomes,11 with the exciting possibility
of improving OS.1 Data from observational epidemiological studies provide a convincing body of evidence
to suggest a considerable survival benefit from habitual
physical activity prediagnosis and postdiagnosis in men
with prostate cancer.4 5 37–40 While these studies provide
useful associations, they cannot infer or establish a causal
relationship, and are subject to bias due to measurement
error, unmeasured and residual confounding, reverse
causation, and self-selection. Consequently, there is a need
for RCTs to directly evaluate the relationship between
exercise (herein delivered as a tailored 2-year exercise
prescription) and OS in men with prostate cancer.1 11 The
INTERVAL-GAP4 protocol outlined in this paper aims to
achieve this ambitious undertaking, and we hypothesise
that a tailored, partially supervised, structured exercise
intervention will deliver greater benefits than incidental
or self-managed physical activity. This study is the first
worldwide to explore the impact of exercise on OS in
prostate cancer.
If it is demonstrated that this exercise intervention
results in a clinically meaningful improvement in patient
survival, then such exercise prescriptions can be immediately implemented worldwide, providing benefits to men
with advanced prostate cancer. Further elucidation of
the mechanisms by which exercise provides this survival
benefit may inform the development of future therapeutic agents as well as improve the synergistic provision
of exercise prescriptions in combination with existing
therapies including chemotherapy, radiation therapy,
enzalutamide and abiraterone.
Following protocol development and endorsement
by the Steering Committee and Research Advisory
Committee, the INTERVAL-GAP4 trial was launched in
December 2015. Following trial launch, a pilot site in
Newton RU, et al. BMJ Open 2018;8:e022899. doi:10.1136/bmjopen-2018-022899

Perth, Western Australia (Edith Cowan University) was
chosen to demonstrate protocol feasibility across the
inaugural year (recruiting from March 2016 to November
2016), whereby the study protocol went through several
iterations to enable minor amendments (from version 1 to
version 4) under the guidance of a Protocol Amendment
Review Committee, with Steering Committee oversight.
Following the established feasibility and demonstration
of the study protocol (with 10 patients randomised at the
pilot site in year 1), along with the concurrent establishment of each trial coordination centre (SCC, ECC), investigator sites worldwide began to open for recruitment in
January 2017 in a staggered process, with six sites open
midyear (July 2017) and a further five sites open by the
end of the year (December 2017). The remaining investigator sites are due to open within the subsequent 12
months (December 2018) and additional sites are being
considered. This study protocol conforms to the Standard Protocol Items: Recommendations for Interventional Trials and the Consensus on Exercise Reporting
Template statements for RCTs and exercise reporting
requirements.41 42

Conclusions
Exercise is rapidly evolving as an emerging and provocative therapy in oncology, with excellent promise to meet
the broad and magnified needs of patients with advanced
prostate cancer. In particular, exercise has the potential
to delay disease progression and extend patient survival
through numerous potential systemic and localised,
mechanical and non-mechanical mechanisms. INTERVAL-GAP4 will be the first RCT to definitively examine if
supervised aerobic and resistance exercise increases OS
among men with mCRPC compared with self-directed
physical activity.
Author affiliations
1
Exercise Medicine Research Institute, Edith Cowan University, Perth, Western
Australia, Australia
2
School of Human Movement and Nutrition Sciences, University of Queensland,
Brisbane, Queensland, Australia
3
School of Medical and Health Science, Edith Cowan University, Perth, Western
Australia, Australia
4
Department of Urology, University of California San Francisco, San Francisco,
California, USA
5
Institute for Health Research, University of Notre Dame Australia, Fremantle,
Western Australia, Australia
6
Department of Epidemiology and Biostatistics, University of California San
Francisco, San Francisco, California, USA
7
Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton,
Alberta, Canada
8
Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
9
School of Medicine, Trinity College Dublin, Dublin, Ireland
10
University Hospitals Bristol, NHS Foundation Trust, Bristol, UK
11
Institute for Health Promotion Research, University of Texas Health, San Antonio,
Texas, UK
12
Department of Epidemiology, Harvard TH Chan School of Public Health, Boston,
Massachusetts, USA
13
Division of Gerontology and Geriatric Medicine, University of Washington, Seattle,
Washington, USA

13

BMJ Open: first published as 10.1136/bmjopen-2018-022899 on 14 May 2018. Downloaded from http://bmjopen.bmj.com/ on 9 July 2018 by guest. Protected by copyright.

approval of the Steering Committee. Approved amendments will be subsequently distributed to individual site
investigators for submission to their human research
ethics committees by the SCC.
Validation of exercise as medicine and its mechanisms
of action will create evidence to change clinical practice.
Accordingly, outcomes of this RCT will be published in
international, high-quality, peer-reviewed journals, and
presented at national and international conferences
or research meetings. Outcomes of this study will also
be delivered to community and consumer-led forums,
and will be presented at local hospital departments and
university seminars. Lastly, evidence derived from this
RCT will be inserted into updated clinical exercise and/
or medical guidelines and position statements within
national and international governing bodies.
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